Patents Assigned to SmithKline Biologicals
  • Publication number: 20140112953
    Abstract: The present invention provides formulations of an immunogenic composition containing a purified inactivated Dengue virus, and method for producing them.
    Type: Application
    Filed: May 25, 2012
    Publication date: April 24, 2014
    Applicant: Glaxo SmithKline Biologicals sa
    Inventors: Veronique Henderickx, Olivier Le Bussy, Dominique Ingrid Lemoine, Frederic Mathot
  • Patent number: 6103519
    Abstract: A composite particle comprising at least two polypeptides corresponding to all or part of a protein having the biological activity of one of the hepatitis B surface antigens, wherein the particle presents at least two antigenic determinants provided by the S-protein, preS2-protein or preS1-protein, said particle optionally further comprising host specific lipids. The invention also provides a modified hepatitis B surface antigen L protein which may be used alone or incorporated into such composite particles.A particular embodiment of the modified L protein (L*) comprises residues 12-52 followed by residues 133-145 followed by residues 175-400 of the L protein and a particular embodiment of a composite particle has the form (L*, S) where S is the S-protein of HBsAg.Improved hepatitis B vaccines may be prepared following expression of the above immunogens, especially in yeasts such as S. cerevisiae and Hansenula polymorpha.
    Type: Grant
    Filed: May 17, 1995
    Date of Patent: August 15, 2000
    Assignee: SmithKline Biologicals, S.A.
    Inventors: Martin Comberbach, Nigel Harford, Teresa Cabezon, Apolonia Rutgers, Pierre Voet, Eric Jacobs, Cornelis P. Hollenberg, Zbigniew A. Janowicz, Armin J. Merckelbach
  • Patent number: 4857317
    Abstract: The process is applicable to the supernatant of engineered yeast cells disrupted in the presence of a non-ionic detergent; it comprises the precipitation of contaminants by polyethylene glycol and the treatment of this latter supernatant with either a bivalent metal cation or, after eventual ultrafiltration, with ammonium sulfate.
    Type: Grant
    Filed: April 27, 1987
    Date of Patent: August 15, 1989
    Assignee: SmithKline Biologicals
    Inventors: Frans V. Wijnendaele, Daniel Gilles, Guy Simonet